Table E7.

Association between high fractional of exhaled nitric oxide measurements (FeNO >35 parts per billion) and hospitalization risk stratified by ICS use

Adjustment	ICS	No ICS
	(odds ratio [95% confidence interval])	(odds ratio [95% confidence interval])
n	835	459
Adjusted for baseline absolute eosinophil count and month of testing	0.45 (0.28-0.70)	0.79 (0.32-1.77)
Adjusted for demographics,∗ baseline absolute eosinophil count, and month of testing	0.70 (0.53-0.92)	0.86 (0.61-1.22)
Adjusted for demographics, baseline absolute eosinophil count,∗ month of testing, smoking status, pack-years smoking, medications, and comorbidities†	0.72 (0.55-0.95)	0.85 (0.60-1.20)

ICS, inhaled corticosteroids.

^∗Demographics include age, sex, ethnicity. and race.

^†The effect of a high FeNO (>35 parts per billion) on hospitalization risk is estimated by weighting each patient with the inverse propensity score and controlling for the propensity score as a covariate in the model. Medications include immunosuppressive therapy (that includes systemic corticosteroids), angiotensin converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs, and intranasal corticosteroids. Comorbidities include body mass index, smoking history (both current and remote), diabetes, hypertension, coronary artery disease, heart failure, cancer history, immunosuppressive disease, and connective tissue disease.